2. Кускова Т.К., Белова Е.Г. Семейство герпес-вирусов на современном этапе. Лечащий врач. 2004;5:64–9.

3. World Health Organization (WHO) (2004). Adolescent friendly health services: An agenda for change. Protecting young people from HIV and AIDS: The role of health services. Geneva: WHO. URL: http://www.who.int/whosis/whostat/2004/en/

4. Игнатовский А.В. Герпетическая инфекция: диагностика, лечение. Врач. 2012;5:39–43.

5. Looker K.J., Magaret A.S., May M.T., et al. Global and regional estimates of prevalent and incident Herpes simplex virus type 1 infections in 2012. PLoS One 2015;10(10):e0140765. Doi: 10.1371/journal.pone.0140765.

6. Pinninti S.G., Kimberlin D.W. Neonatal herpes simplex virus infections. Semin Perinatol. 2018;42(3):168–75. Doi: 10.1053/j.semperi.2018.02.004.

7. Осидак Л.В., Дриневский В.П., Цыбалова Л.М. и др. Острые респираторные инфекции у детей и подростков: практическое руководство для врачей. СПб., 2010.

8. Федотов В.П., Рыбалкин С.Б., Романцов М.Г. Очерки по иммунокоррекции в дерматовенерологии. СПб., 2005.

9. Xianzhi Jiang, Aziz Alami Chentoufi, Chinhui Hsiang, et al. The herpes simplex virus type 1 latency associated transcript (LAT) can protect neuronal derived C1300 and Neuro2A c ells from Granzyme B induced apoptosis and CD8 T-cell killing. J Virol. 2010;85:2325–32. Doi: 10.1128/JVI.01791-10.

10. Самгин М.А., Халдин А.А. Простой герпес (дерматологические аспекты). М., 2002, 160 с.

11. Львов Н.Д. Герпесвирусы человека – системная, интегративная, лимфопролиферативная иммуноонкопатология. Русский медицинский журнал. 2012;22:1133–8.

12. Bosch F.X., Broker T.R., Forman D., et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31(Suppl. 7):H1–31. Doi: 10.1016/j.vaccine.2013.10.003.

13. Park I.U., Introcaso C., Dunne E.F. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis. 2015;61(Suppl. 8):849–55. Doi: 10.1093/cid/civ813.

14. Dobson S., Deeks S., Money D. National Advisory Committee on Immunization (NACI). Statement on human papillomavirus vaccine. An advisory committee statement (ACS). Can Communt Dis Rep. 2007;33(ACS-2):1–31. PMID: 17520773.

15. Moore R.A., Fornika D.J., Moravan V., et al. HPV type distribution in North America – apopulation-based study of 5000 British Columbia women. 23rd International Papillomavirus Conference & Clinical Workshop. Prague, September 1 to 7, 2006.

16. Рахматулина М.Р., Кицак В.Я., Большенко Н.В. Современные методы профилактики развития онкологических заболеваний шейки матки у больных папилломавирусной инфекцией. Вестник дерматологии и венерологии. 2013;6:40–9.

17. Кубанов А.А. Современные подходы к лечению папилломавирусной инфекции кожи и слизистых оболочек. Вестник дерматологии и венерологии. 2005;4:8–12.

18. Tay S.K. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study. Int J STD AIDS. 1996;7(4):276–80. doi: 10.1258/0956462961917960.

19. Beran J., Špajdel M., Katzerová V., et al. Inosine Pranobex Significantly decreased the case-fatality rate among PCR positive elderly with SARS-CoV-2 at three nursing homes in the Czech Republic. Pathogens. 2020;9(12):1055. Doi: 10.3390/pathogens9121055.

20. Bartovská Z., Andrle F., Beran O., Data from the first wave of Covid-19 from the Central Military Hospital, Prague, Czech Republic. Epidemiol Mikrobiol Imunol. 2020;69(4):164–71.

21. Sliva J., Pantzartzi C.N., Votava M. Inosine Pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases. Adv Ther. 2019;36:1878–905. Doi: 10.1007/s12325-019-00995-6.

22. You Y., Wang L., Li Y., et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes la-bialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42:596–601. Doi: 10.1111/1346-8138.12845.

23. Lasek W., Janyst M., Wolny R., et al. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm. 2015;65(2):171–80. Doi: 10.1515/acph-2015-0015.

24. Petrova M., Jelev D., Ivanova A., Krastev Z. Isoprinosine Affects Serum Cytokine Levels in Healthy Adults. J Interf Cytokine Res. 2010;30:223–28. Doi: 10.1089/jir.2009.0057.

25. Milano S., Dieli M., Millott S., Miceli M D, Maltese E, Cillari E. Effect of isoprinosine on IL-2, IFN- gamma and IL-4 production in vivo and in vitro. Int J Immunopharmacol. 1991;13:1013–1018. Doi: 10.1016/0192-0561(91)90055-c.

26. Beran J., Šalapová E,. Špajdel M., Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016;16(1):648. Doi: 10.1186/s12879-016-1965-5.

27. Ahmed R.S., Newman A.S., O’Daly J., et al. Inosine acedoben dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: a clinical trial supporting anti-viral indications. Int Immunopharmacol. 2017;42:108–14. Doi: 10.1016/j.intimp.2016.11.023.

28. Linhares R.E.C., Wigg M.D., Lagrota M.H.C., Nozawa C.M. The in vitro anti-viral activity of isoprinosine on simian rotavirus (SA-11) Braz J Med Biol Res. 1989;22:1095–103.

29. You Y., Wang L., Li Y., et al. Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients. J Dermatol. 2015;42(6):596–601. Doi: 10.1111/1346-8138.12845.

30. Majewska A., Lasek W., Janyst M., Mlynarczyk G. In vitro inhibition of HHV-1 replication by inosine pranobex and interferon-α. Acta Pol Pharm. 2016;73(3):637–44.

31. Tobolska S., Terpilowska S., Jaroszewski J., Siwicki A.K. Genotoxicity and mutagenicity of inosine pranobex. J Vet Res. 2018;62(2):207–13. Doi: 10.2478/jvetres-2018-0030.

32. Исаков В.А., Исаков Д.В., Стуколкина Н.Е. Возможности терапии респираторных инфекций у часто болеющих пациентов. Клиническая фармакология и терапия. 2018;27(2):14–21.

33. Janíčková O., Ančicová L., Briestenska K., Mistrikova J. The effect of Isoprinosine treatment on persistent infection of Balb/c mice infected with murine gammaherpesvirus 68. Acta Virol. 2017;61(1):32–8. Doi: 10.4149/av_2017_01_32.

34. Kumar R., Gupta N., Kodan P., et al. Battling COVID-19: Using old weapons for a new enemy. Trop Dis Travel Med Vaccines. 2020;6:1–10. Doi: 10.1186/s40794-020-00107-1.

35. Караулов А.В. Иммуномодуляторы в профилактике и лечении респираторных инфекций у детей. Фарматека. 2012;1:10–3.

36. Савенкова М.С., Балакирева Г.М., Румянцева И.Г. Показания и опыт применения инозина пранобекса в педиатрической практике. Consilium Medicum (Педиатрия). 2017;4:52–5.